Viruses and bacteria. Recombinant MVA expressing the human tyrosinase gene or the human Her-2/neu gene under control of the VV-specific natural early/late promoter P7.5 have been previously described (18, 40). The 975-nt ORF (MVA093L) encoding the VV H3 protein was derived from strain MVA (sequence corresponds to nt 83, 139; GenBank accession no. U94848) and was cloned into vector pEM7/Zeo (Invitrogen). The entire H3L gene was cut and inserted into the unique PmeI site of the pIII-∆HR-P7.5 MVA transfer vector plasmid, placing it under the control of the VV-specific natural early/late promoter P7.5. Recombinant MVA P7.5 H3L was generated, propagated, and titered as recently described (39). A DNA sequence containing the entire sequence of the PK1L VV-specific early promoter was amplified by PCR from plasmid pIIIdHR-P7.5 using primers 5′-CCCCGGATCCCATGATTAA-GATTGGTCTTTCGGTGGCTGGGTACCC-3′ and 5′-GGGGGAGCTCAGGCCTGCTAGCGTCTGAAACGAGACGCTAATTAGTGTATATTTTTTC-3′ (sites for restriction enzymes BamHI and SacI are underlined). A DNA sequence containing the entire sequence of the P11 VV-specific late promoter was amplified by PCR from plasmid pUCII LZdel P7.5 (40) using primers 5′-CCCCGGATCCACAAACATGTCCACTAGAAGCGATGC-3′ and 5′-CCCCGAGCTCAGGCCTGCTAGCTAATT-TATAGCATAGAAAAAACCCCCCATGAAATTCTCC-3′ (sites for restriction enzymes BamHI and SacI are underlined). The MVA transfer vectors pIII∆HR-PK1L and pIII∆HR-P11 were generated by insertion of the resulting 151-bp P11 late promoter or the 145-bp PK1L early promoter DNA fragment between the unique BamHI and SacI restriction sites of pIII∆HR-P7.5, thereby deleting the P7.5 VV-specific early/late promoter originally contained in this plasmid. MVA vector plasmids pIII∆HR-PK1L-OVA and pIII∆HR-P11-OVA were constructed by inserting the entire ovalbumin gene derived from plasmid pC-OVA (a gift from H. Wagner, Institute of Immunology, Munich, Germany) into a unique SacI restriction site of pIII∆HR-PK1L and pIII∆HR-P11, placing it under control of the PK1L and the P11 promoter, respectively. Deletion mutant virus MVA ∆B8R, the revertant deletion mutant MVA ∆H3L P7.5 H3L, and recombinant OVA-expressing viruses were obtained by homologous recombination using transfer plasmids pDK1L-176R, pIII∆HR-PK1L-OVA, and pIII∆HR-P11-OVA for MVA or pDK1L-093L for MVA P7.5 H3L, respectively, followed by the transient K1L-based host-range selection protocol, as previously described (41). DNA genomes of recombinant and deletion mutant viruses were analyzed by PCR. For in vitro and in vivo assays, all VVs were purified by ultracentrifugation through a 36% sucrose cushion. Vaccine preparations were reconstituted in 1 mM Tris, pH 7.4, and 120 mM NaCl saline buffer. L. monocytogenes-OVA-specific protection was determined by analyzing the bacterial load in spleens and livers by plating out serial dilutions as previously described (42).
